Liver Complications Following Treatment of Hematologic Malignancy With Anti‐CD22‐Calicheamicin (Inotuzumab Ozogamicin)
George B. McDonald, James W. Freston, James L. Boyer, Laurie D. DeLeve – 18 August 2018 – Treatment of hematological malignancy with antibody‐drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen‐expressing tumor cells, but may also injure hepatic sinusoids (sinusoidal obstruction syndrome; SOS).